Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM08XS2)

Drug Name

ERIC-1 Drug Info

Synonyms

UJ13A; NCAM antagonist, Imperial Cancer Research Technology; ERIC-1, ICRT; ERIC-1, Imperial CancerResearch Technology

Indication

Disease Entry	ICD 11	Status	REF
Solid tumour/cancer	2A00-2F9Z	Terminated	[1]

Cross-matching ID

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Clinical Trial Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Neural cell adhesion molecule (NCAM)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
IMGN901	DMIUC3M	Solid tumour/cancer	2A00-2F9Z	Phase 2	[3]
FGLL	DMY61GX	Alzheimer disease	8A20	Phase 1	[4]
------------------------------------------------------------------------------------

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Neural cell adhesion molecule (NCAM)	TTUBJQ3	NOUNIPROTAC	Antagonist	[2]

------------------------------------------------------------------------------------

References

1	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800004519)
2	Monoclonal antibody UJ13A recognizes the neural cell adhesion molecule (NCAM). Int J Cancer. 1989 Dec 15;44(6):1062-8.
3	Lorvotuzumab mertansine, a CD56-targeting antibody-drug conjugate with potent antitumor activity against small cell lung cancer in human xenograft models. MAbs. 2014 Mar-Apr;6(2):556-66.
4	An NCAM mimetic, FGL, alters hippocampal cellular morphometry in young adult (4 month-old) rats. Neurochem Res. 2013 Jun;38(6):1208-18.